Towards Tailored Radiopeptide Therapy
| Autor: | Martin A. Walter, Piotr Radojewski, Jan Müller-Brand, Matthias Briel, Philippe Brunner, Rebecca A. Dumont, Nicolas Marincek, Helmut R. Mäcke |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty medicine.medical_treatment 610 Medicine & health Neuroendocrine tumors Octreotide Competing risks 030218 nuclear medicine & medical imaging Targeted therapy 03 medical and health sciences 0302 clinical medicine Combined treatment Internal medicine medicine Humans Somatostatin receptor 2 Radiology Nuclear Medicine and imaging In patient Aged Aged 80 and over business.industry General Medicine Middle Aged medicine.disease Survival Analysis 3. Good health Neuroendocrine Tumors Somatostatin 030220 oncology & carcinogenesis Toxicity Physical therapy Female Radiopharmaceuticals business |
| Zdroj: | Eur J Nucl Med Mol Imaging Radojewski, Piotr; Dumont, Rebecca; Marincek, Nicolas; Brunner, Philippe; Mäcke, Helmut R; Müller-Brand, Jan; Briel, Matthias; Walter, Martin Alexander (2015). Towards tailored radiopeptide therapy. European journal of nuclear medicine and molecular imaging, 42(8), pp. 1231-1237. Springer 10.1007/s00259-015-3030-9 |
| DOI: | 10.1007/s00259-015-3030-9 |
| Popis: | PURPOSE Somatostatin receptor-targeted radiopeptide therapy is commonly performed using single radioisotopes. We evaluated the benefits and harms of combining radioisotopes in radiopeptide therapy in patients with neuroendocrine tumor. METHODS Using multivariable-adjusted survival analyses and competing risk analyses we evaluated outcomes in patients with neuroendocrine tumor receiving (90)Y-DOTATOC, (177)Lu-DOTATOC or their combination. RESULTS (90)Y-DOTATOC plus (177)Lu-DOTATOC treatment was associated with longer survival than (90)Y-DOTATOC (66.1 vs. 47.5 months; n = 1,358; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|